- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
NovoNordisk Gets CDSCO Panel Nod To Study anti-diabetic FDC Cagrilinitide,Semaglutide
New Delhi: Advising to submit the trial safety and efficacy data, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) has given its nod to drug major Novo-Nordisk for conducting the phase III clinical trial of anti-diabetic fixed dose combination drug containing Cagrilinitide and Semaglutide.
This came after the drug maker Novo-Nordisk presented the proposed Phase IIIa trial protocol no. NN9838-4608, Version 03 dated 24Jun2022 (REDEFINE) for FDCs anti-diabetic drug Cagrilinitide plus Semaglutide before the committee.
The nod is subjected to condition that the firm should submit the trial safety and efficacy data to the committee for review and further initiation of the extension phase.
Cagrilintide is a long-acting amylin analogue intended for once-weekly treatment being developed by Novo Nordisk, as a subcutaneous formulation, for the treatment of obesity and non-alcoholic steatohepatitis.
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. GLP-1 is a physiological hormone that promotes glycemic control via several different mechanisms, including insulin secretion, slowing gastric emptying, and reducing postprandial glucagon secretion. The homeostasis of glucose is dependent on hormones such as insulin and amylin, which are secreted by the beta cells of the pancreas.
Also Read:NovoNordisk Gets CDSCO Panel Okay To Study Anti-Diabetic Drug Semaglutide
At recent SEC meeting for endocrinology and metabolism held on 9th September 2022,the expert panel reviewed the proposal presented by the drug marker Novo-Nordisk for the FDCs anti-diabetic drug Cagrilinitide plus Semaglutide Phase IIIa trial protocol no.NN9838-4608,Version 03 dated 24Jun2022 (REDEFINE)
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.